Most recent by Lee Greenberger, PhD
Consolidative HSCT may not be necessary for some patients with mantle cell lymphoma
SAN DIEGO — Autologous hematopoietic stem cell transplantation did not benefit adults with mantle cell lymphoma in first complete remission after induction, according to randomized phase 3 data presented at ASH Annual Meeting and Exposition.
First-line regimen improves PFS in chronic lymphocytic leukemia
SAN DIEGO — A multidrug combination significantly improved survival for certain patients with leukemia compared with standard chemoimmunotherapy, according to results of the randomized phase 3 AMPLIFY study.
Study yields 'encouraging' preliminary data for navitoclax combination in myelofibrosis
SAN DIEGO — Navitoclax added to ruxolitinib led to a significant improvement in spleen volume reduction compared with placebo among patients with untreated myelofibrosis, study results presented at ASH Annual Meeting and Exposition showed.
Pelabresib-ruxolitinib combination reduces spleen volume, symptom score in myelofibrosis
Pelabresib plus ruxolitinib conferred benefit to Janus kinase inhibitor-naive patients with myelofibrosis, according to study results presented at ASH Annual Meeting and Exhibition.
Zanubrutinib prolongs PFS with fewer cardiac events vs. ibrutinib in advanced CLL, SLL
NEW ORLEANS — Zanubrutinib significantly prolonged PFS compared with ibrutinib among patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, results of the phase 3 ALPINE study showed.
Copanlisib regimen improves outcomes in pretreated follicular, marginal zone lymphoma
The addition of copanlisib to rituximab extended PFS among patients with relapsed follicular lymphoma or marginal zone lymphoma, according to a subset analysis of the randomized phase 3 CHRONOS-3 trial.
Inpatient hospitalization, mortality high among patients with cancer, COVID-19
Patients with cancer who contracted COVID-19 had high risk for inpatient hospital admission and death, according to study results presented during the virtual ASCO Annual Meeting.
‘Hub-and-spoke’ initiatives aim to improve minority access to blood cancer clinical trials
The Leukemia & Lymphoma Society will collaborate with three major cancer centers to provide minority and other underserved populations with greater access to blood cancer clinical trials.
Approval of new CAR-T may have ‘immediate impact’ on treatment of large B-cell lymphoma
The uptake of chimeric antigen receptor T-cell therapy has been sluggish despite its tantalizing promise to provide a cure for a large proportion of patients with advanced large B-cell lymphoma.
Real-world CAR T-cell therapy as safe, effective as in clinical trial setting
Axicabtagene ciloleucel administered as standard of care appeared as safe and effective as when given during the agent’s pivotal clinical trial, according to study results published in Journal of Clinical Oncology.